82475-03-4

Basic information

• Product Name: Baicalin methyl ester
• Synonyms: Baicalin methyl ester;5,6-Dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl beta-D-glucopyranosiduronic acid methyl ester
• CAS NO: 82475-03-4
• Molecular Formula: C₂₂H₂₀O₁₁
• Molecular Weight: 460.3876
• Mol File: 82475-03-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 268-270 °C
• Boiling Point: 754.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.631±0.06 g/cm3(Predicted)
• PKA: 5.90±0.40(Predicted)
• CAS DataBase Reference: Baicalin methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Baicalin methyl ester(82475-03-4)
• EPA Substance Registry System: Baicalin methyl ester(82475-03-4)

Safety Data

• Hazardous Substances Data: 82475-03-4(Hazardous Substances Data)

Usage

General Description

Baicalin methyl ester is a chemical compound that is a methyl ester derivative of baicalin, a flavonoid compound found in the roots of Scutellaria baicalensis, a traditional Chinese medicinal plant. Baicalin methyl ester is known for its various biological activities, including anti-inflammatory, antioxidant, and neuroprotective properties. It has been studied for its potential therapeutic applications in treating conditions such as neurodegenerative diseases, cancer, and inflammatory disorders. Baicalin methyl ester is also being researched for its potential use in skincare and cosmetic products due to its antioxidant properties. Overall, baicalin methyl ester is a promising compound with potential applications in both pharmaceutical and cosmetic industries.

Upstream product

• 13165-72-5 chlorosulfite de methyle 
• 21967-41-9 baicalin 
• 67-56-1 methanol 

Downstream Products

• 491-67-8 5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one 
• 480-11-5 oroxylin A 
• 82475-02-3 5-hydroxy-6-methoxyflavone-7-O-β-D-glucuronide methyl ester 
• 29550-13-8 5,6-dihydroxy-7-methoxyflavone 
• 57396-78-8 Oroxin A 

Relevant articles and documents

An unambiguous and practical synthesis of Oroxylin A: a commonly misidentified flavone

Oroxylin A, a major flavonoid in the extracts of Oroxylum indicum as well as Scutellaria baicalensis possesses useful medicinal properties. Many of the published routes claiming the synthesis of Oroxylin A (1) have in fact led to a regioisomer Negletein that was misinterpreted as Oroxylin A. In the present work, we describe a novel, straight-forward and scalable semi-synthetic approach for rapid access to the title compound, the structure of which is unambiguously secured by NMR and X-ray crystallographic analysis of a derivative. This work also encompasses the synthesis of a glycosylated derivative of Oroxylin A viz OAGME (2), which has marked pharmacological importance.

Crystal structures of the flavonoid Oroxylin A and the regioisomers Negletein and Wogonin

The flavonoid Oroxylin A (6-methoxychrysin or 5,7-dihydroxy-6-methoxy-2- phenyl-4H-chromen-4-one, C16H12O5) and its regioisomers are of increasing interest for a variety of bioactive functions and their pharmaceutical formulation is of importance. Previous difficulties in the separation and misidentification of Oroxylin A from its regioisomers Wogonin (8-methoxychrysin or 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one) and Negletein (5,6- dihydroxy-7-methoxyflavone or 5,6-dihydroxy-7-methoxy-2-phenyl-4H-chromen- 4-one) render its full structural and powder X-ray characterization highly desirable. The low-temperature (100 K) crystal structures of Oroxylin A, Negletein and Wogonin sesquihydrate are reported for the first time. Wogonin crystallizes in two related but distinct hydrated forms. These have very similar powder diffractograms, indicating that such issues need to be addressed for its pharmaceutical formulation.

Baicalin derivative and application of baicalin and baicalin derivative in preparing drugs for treating bovine viral disease

The invention provides a baicalin derivative and an application of baicalin and baicalin derivative in preparing drugs for treating bovine viral disease and belongs to the technical field of medicines. According to the invention, the baicalin derivative u